Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · May 02, 2018

Trastuzumab Plus Capecitabine vs Lapatinib Plus Capecitabine in HER2+ Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxanes

The Breast

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Breast
A Randomized Phase II Trial of Trastuzumab Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxanes: WJOG6110B/ELTOP
Breast 2018 Aug 01;40(xx)67-75, T Takano, J Tsurutani, M Takahashi, T Yamanaka, K Sakai, Y Ito, J Fukuoka, H Kimura, H Kawabata, K Tamura, K Matsumoto, K Aogi, K Sato, K Nishio, K Nakagawa, T Saeki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading